Alzheimer's Disease

A new observational study is building on a body of data finding a correlation between afternoon naps and improved mental agility. The research hypothesizes afternoon naps may help moderate age-related neuroinflammation helping keep the brain healthy.

Although yet to be published in a peer-reviewed journal, pharmaceutical company Eli Lilly has announced promising results from one of its Phase 2 human trials testing an experimental Alzheimer’s disease drug designed to slow cognitive decline.

A robust new study has comprehensively demonstrated how SARS-CoV-2, the coronavirus that causes COVID-19, can infect the brain and central nervous system. The study validates a growing body of research attributing neurological issues to COVID-19.

A new study has identified three different molecular subtypes of Alzheimer's disease. The research suggests these subtypes are so distinct from one another they could account for previous clinical trial failures and inconsistent translational studies.

Research into a rare type of dementia has uncovered a genetic mutation that results in dysfunctional white blood cells and a breakdown of the blood-brain barrier, a mechanism that may play a role in common types of dementia such as Alzheimer's.

A novel wearable that stimulates the olfactory system using electrical pulses has been proposed as a way to prevent or slow dementia-related neurodegeneration. A dysfunctional sense of smell is suspected to be one of the earliest signs of Alzheimer’s.

Scientists have identified a protein implicated in the progression of Alzheimer's disease that appears highly regulated by the circadian rhythm, helping them join the dots between the two and providing a potential new therapeutic target.

A team from the Washington University School of Medicine in St. Louis has come up with a technique it says can detect one of the biomarkers of Alzheimer's in cerebrospinal fluid, which could lead to earlier diagnoses and more effective treatments.

A new test that can analyze levels of two proteins in the blood of those with mild memory loss has demonstrated the potential to help predict the risk of them going on to develop Alzheimer’s within a timeframe of two to four years.

Research has suggested that anxiety is an early indicator for Alzheimer's disease, which often follows mild cognitive decline (MCI). A new study has now found a link between anxiety and an increased rate of progression from MCI to Alzheimer's disease.

A new study into the gut microbiome and Alzheimer's has shown that shifts in bacterial diversity are associated with inflammation and heightened numbers of amyloid plaques in the brain, one of the hallmarks of the condition.

An experimental drug has been shown to slow the progression and prolong survival of patients suffering from the neurodegenerative disease ALS. With Phase 2 human trials complete, the company developing the treatment is working to accelerate its approval.